Multiparametric prognostic evaluation of biological factors in primary breast cancer.
about
DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients.The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.The relationship between prognostic and predictive factors in the management of breast cancer.Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer.uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomasStromal cell cathepsin D expression and long-term survival in breast cancer.Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extractsProliferative markers as prognostic and predictive tools in early breast cancer: where are we now?Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factorsEmerging biomarkers in breast cancer care.Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases.Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?The role of thymidine kinase in cancer diseases.Divergent effect of TGFbeta1 on growth and proteolytic modulation of human prostatic-cancer cell lines.The biochemistry of cancer dissemination.New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes.Modulation of the estrogen-regulated proteins cathepsin D and pS2 by opioid agonists in hormone-sensitive breast cancer cell lines (MCF7 and T47D): evidence for an interaction between the two systems.Predicting distant dissemination in patients with early breast cancer.Tissue extraction procedures for investigation of urokinase plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in human breast carcinomas.High-dose therapy with peripheral blood stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive metastatic breast cancers
P2860
Q32160071-03114A64-FE6B-4051-A77C-FE022CD52166Q33538432-23B83F0E-2DFE-461B-AAA0-D402CCE0474CQ33538455-C55D2B7D-2E88-4E66-825F-520E8E644A6FQ33676610-8142E3D6-D4E5-4029-83DA-023685832FE6Q34160701-E848A210-A00B-4EA7-AA4A-DCB6F505A7B2Q35580701-0DCA4084-3DD4-4CBE-A91D-FF9406B14559Q35977650-A53B889D-048E-4A2A-BA33-78F8AA4CDC44Q36079902-6A5BC40E-8EDD-49A1-80BC-2E638694C6DFQ36114789-10F73785-39E1-4C98-B483-21ECDCA7C4EEQ36115751-2B13DF19-1674-4104-974F-9D88D139D0B6Q36175746-9AE5557F-70D0-4D3A-83DF-7FC0A68DFD05Q36292147-B2E0BE91-AB5E-4374-B53B-8188A275E141Q36292537-ED9FF986-A6C4-43F0-876E-4A8291362831Q36617616-76491131-2FBE-412A-BD9C-9DF0DA833C65Q36617844-221206B3-7BC5-44AC-BBD0-4BC9472A8F37Q36620181-38FB9BDF-C2FC-4541-A1B9-438F60960E9FQ37779305-81AF026B-E96F-4EA9-A6AD-D6F91A5FF3B8Q37837982-C45D6768-059A-46A5-A4E7-9E16FC9A5185Q37986561-25338CA1-A763-4F2C-8397-D2A94299F3B7Q38088840-0584570F-36F3-45E7-8260-41A0AC491B41Q41192340-83854839-CE04-4FDC-B85C-C47E3050F10CQ41547351-0B4C47EA-867E-4287-B0E0-EE259F665E55Q41702637-70C9B653-3645-4BAC-9DB3-581E8F8D38A1Q44350661-CA494084-DF54-4693-9866-197EE6F3E9C4Q44648560-7BC6A581-C296-481E-A32B-A732951B62C6Q47718780-6535DF8B-E54B-4AA9-BE97-F5ECA16D3974Q58215312-65DEE6ED-6834-445A-B1F4-F3E0CCB8D240
P2860
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
@en
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
@nl
type
label
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
@en
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
@nl
prefLabel
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
@en
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
@nl
P2093
P356
P1476
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
@en
P2093
Deytieux S
Ferrero-Poüs M
Le Doussal V
Spyratos F
Tubiana-Hulin M
P304
P356
10.1093/JNCI/84.16.1266
P407
P577
1992-08-01T00:00:00Z